Advancements and Clinical Dynamics of mRNA Vaccines: A Comprehensive Review

Abstract

Messenger RNA (mRNA) vaccines represent a paradigm shift in vaccinology, leveraging in vitro transcription (IVT) to produce antigen-encoding transcripts that are delivered via lipid nanoparticle (LNP) carriers. This review examines the molecular and biophysical principles underlying IVT mRNA design, LNP formulation, and host cellular interactions that drive protective immunity. Emphasis is placed on veterinary applications, drawing comparative host-range parallels to elucidate species-specific immune responses. The review integrates recent advances in sequence optimization, nucleoside modification, and delivery technologies that collectively enhance translational efficiency and immunogenicity. Challenges including reactogenicity, thermostability, and antigenic drift are discussed within the context of veterinary pathogen control. Two key publications provide the foundation for this analysis: Xu et al. (2025) on sequence-to-system enhancement of IVT mRNA effectiveness, and Pilkington et al. (2021) on LNP mRNA vaccines across infectious disease frontiers [1, 2].

1. Introduction

Conventional vaccine platforms, including live-attenuated, inactivated, and subunit vaccines, have long served as cornerstones of infectious disease management in both human and veterinary medicine. However, these platforms face limitations in production speed, antigenic breadth, and adaptability to emerging pathogens. mRNA vaccines circumvent many of these constraints by encoding antigenic proteins directly within synthetic transcripts, enabling rapid platform reconfiguration in response to antigenic variation. The veterinary sector has historically benefited from parallel advances in human vaccinology, and mRNA platforms now offer transformative potential for controlling viral, bacterial, and parasitic diseases in livestock, companion animals, and wildlife.

The core innovation of mRNA vaccines lies in their ability to instruct host cells to produce defined antigens endogenously, thereby eliciting both humoral and cell-mediated immune responses without the risks associated with live pathogen administration. Xu et al. (2025) provided a comprehensive framework for enhancing IVT mRNA vaccine effectiveness through systematic sequence design, cap analog optimization, and untranslated region (UTR) engineering [1]. Concurrently, Pilkington et al. (2021) delineated the critical role of lipid nanoparticle formulations in protecting mRNA from extracellular nucleases and facilitating cytosolic delivery across diverse target species [2]. Together, these works underscore the interdependence of RNA chemistry and delivery science in achieving potent and durable immunity.

2. Molecular Architecture of IVT mRNA

In vitro transcription produces synthetic mRNA that mimics natural eukaryotic transcripts. The canonical IVT mRNA comprises a 5' cap, 5' and 3' untranslated regions (UTRs), an open reading frame (ORF) encoding the target antigen, and a polyadenylated tail. Each component exerts distinct influences on translational efficiency, cellular stability, and innate immune sensing.

2.1 5' Cap and Cap Analogs

The 5' cap (m7GpppN) is essential for ribosomal recruitment and protection against 5'-to-3' exonucleolytic degradation. Xu et al. (2025) described the use of anti-reverse cap analogs (ARCA) that ensure correct cap orientation, thereby maximizing translation initiation fidelity [1]. Cap structures can be further modified to reduce recognition by cytoplasmic pattern recognition receptors such as retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated protein 5 (MDA5).

2.2 Untranslated Regions and Codon Optimization

UTRs derived from highly expressed cellular genes, such as alpha-globin or beta-globin, confer enhanced translation by stabilizing secondary structures and recruiting RNA-binding proteins. Xu et al. (2025) emphasized that systematic screening of UTR combinations can significantly modulate mRNA half-life and protein output [1]. Codon optimization of the ORF to match the host species' tRNA pool further improves translational efficiency. For veterinary vaccines, codon usage tables must be tailored to the target species (e.g., Gallus gallus, Bos taurus, Canis lupus familiaris).

2.3 Nucleoside Modifications

Incorporation of modified nucleosides, such as pseudouridine (Ψ) or N1-methylpseudouridine (m1Ψ), suppresses activation of endosomal Toll-like receptors (TLR3, TLR7, TLR8) and cytosolic sensors. This reduction in innate immune activation prevents premature translational shutdown and enhances antigen yield. Pilkington et al. (2021) noted that nucleoside modification is a crucial design element for avoiding excessive inflammation while maintaining immunogenicity [2].

2.4 Polyadenylation

A poly(A) tail of 100 to 150 adenosine residues stabilizes the transcript and promotes circularization via poly(A)-binding protein (PABP) interactions with the 5' cap. Tail length optimization is species-dependent and can be encoded in the DNA template or added enzymatically after transcription.

3. Lipid Nanoparticle Delivery Systems

Naked mRNA is rapidly degraded by extracellular ribonucleases and fails to cross the plasma membrane efficiently. Lipid nanoparticles overcome these barriers by encapsulating mRNA within a lipid bilayer that facilitates endocytosis and endosomal escape.

3.1 Composition and Formulation

LNPs typically consist of four components: an ionizable cationic lipid, a zwitterionic phospholipid (e.g., 1,2-distearoyl-sn-glycero-3-phosphocholine, DSPC), cholesterol, and a polyethylene glycol (PEG)-lipid conjugate. The ionizable lipid is the key driver of endosomal release: at acidic pH within endosomes, it acquires a positive charge, disrupting the anionic endosomal membrane and releasing mRNA into the cytoplasm. Pilkington et al. (2021) reviewed structure-activity relationships of ionizable lipids, highlighting how lipid pKa and tail length influence transfection efficiency and biodistribution [2].

3.2 Species-Specific Biodistribution

Delivery to antigen-presenting cells (APCs) at the injection site and draining lymph nodes is critical for immunogenicity. LNP size (typically 80 to 120 nm) and surface charge affect lymphatic uptake. In veterinary species, anatomical differences in lymphatic drainage and immune cell populations may require formulation adjustments. Intramuscular injection is the most common route for LNP-mRNA vaccines, but intradermal and subcutaneous routes are under investigation for livestock.

3.3 Thermostability and Storage

Unlike traditional vaccines that require refrigeration, LNP-mRNA vaccines require cold chain storage, typically at -20°C or -80°C. Lyophilization and trehalose-based formulations are being explored to improve thermostability for field use in veterinary settings, where cold chain logistics are often limited. Pilkington et al. (2021) discussed the importance of formulation excipients in maintaining particle integrity during freeze-thaw cycles [2].

4. Immunological Dynamics

4.1 Antigen Presentation and Humoral Immunity

Upon cytosolic delivery, mRNA is translated by ribosomes, and the resulting antigenic protein undergoes proteasomal degradation and loading onto major histocompatibility complex class I (MHC-I) molecules. This process primes CD8+ cytotoxic T lymphocyte (CTL) responses. Simultaneously, secreted or membrane-bound antigens are taken up by APCs via phagocytosis or receptor-mediated endocytosis, leading to MHC-II presentation and CD4+ T helper cell activation. B cell activation occurs through follicular dendritic cell antigen display and T follicular helper cell engagement, resulting in germinal center formation, affinity maturation, and antibody class switching.

4.2 Innate Immune Sensing and Adjuvant Effect

The mRNA molecule itself acts as an intrinsic adjuvant through recognition by TLR3/7/8, RIG-I, and protein kinase R (PKR). Moderate innate activation enhances dendritic cell maturation and cytokine secretion (e.g., type I interferons, IL-12). However, excessive activation can suppress translation and cause reactogenicity. Xu et al. (2025) highlighted strategies to balance innate sensing by optimizing nucleoside content and purification protocols to remove double-stranded RNA (dsRNA) contaminants [1].

4.3 Duration of Immunity

Antibody persistence following mRNA vaccination depends on antigen expression kinetics, germinal center longevity, and the formation of long-lived plasma cells. In veterinary species, booster regimens are typically required to achieve protective titers. Comparative studies in livestock have shown that mRNA vaccines can induce neutralizing antibodies for months, though data on memory B cell and T cell durability remain limited.

5. Veterinary Applications

5.1 Livestock Pathogens

mRNA vaccines have been experimentally developed against numerous livestock viruses, including foot-and-mouth disease virus, bluetongue virus, and classical swine fever virus. The platform's rapid reconfiguration is particularly advantageous for controlling emerging viral strains, such as highly pathogenic avian influenza (H5N1) in poultry and wild birds. The ability to update the ORF alone without altering the LNP formulation allows rapid response to antigenic drift. Link to Highly Pathogenic Avian Influenza (H5N1) in Poultry and Wild Birds: Clinical Signs, Transmission Dynamics, and Surveillance Maps.

5.2 Companion Animals

In companion animals, mRNA vaccines are being investigated for canine distemper virus, Canine Coronavirus variants, and Feline Leukemia Virus progressive infection. The platform offers a safety advantage over live-attenuated vaccines in immunocompromised animals. LNP-mRNA vaccines can also be designed to encode multiple antigens from a single construct, enabling multivalent protection.

5.3 Wildlife and Zoonotic Reservoirs

Vaccination of wildlife reservoirs (e.g., white-tailed deer for tick-borne parasites, raccoons for rabies) presents challenges in delivery and thermostability. Oral mRNA vaccines formulated in baits are under development, using enteric-coated LNPs resistant to gastrointestinal degradation. Pilkington et al. (2021) discussed the potential for LNP-mRNA vaccines to target zoonotic pathogens at the animal-human interface [2].

5.4 Aquatic Species

For aquaculture, mRNA vaccines against pathogens such as viral hemorrhagic septicemia virus and infectious salmon anemia virus are being explored. Injection remains the primary route for finfish, and formulation parameters must account for lower body temperatures (typically 10-15°C) that reduce mRNA translation rates. Link to Ichthyophthirius multifiliis (White Spot Disease) in Farmed Fish: Advances in Molecular Detection and Treatment.

6. Challenges and Limitations

6.1 Reactogenicity and Inflammatory Responses

Innate immune sensing, while beneficial for adjuvanticity, can cause injection site reactions, fever, and transient malaise in sensitive species. Veterinary patients may not report mild symptoms, but decreased feed intake or weight gain may indicate reactogenicity. Xu et al. (2025) emphasized the need for optimized purification methods to remove dsRNA contaminants that hyperactivate inflammatory pathways [1].

6.2 Antigenic Variation and Booster Strategies

RNA viruses exhibit high mutation rates, necessitating periodic antigen updates. mRNA vaccine platforms can accommodate rapid sequence modifications, but booster intervals must be determined empirically for each species and pathogen. For example, West Nile Virus in horses may require annual revaccination with updated ORFs reflecting circulating strains.

6.3 Thermostability and Cold Chain

The requirement for frozen storage limits deployment in remote or resource-limited veterinary settings. Advances in lyophilized LNP formulations and room-temperature stable mRNA complexes are critical for expanding access. Pilkington et al. (2021) noted that sugar-based excipients can improve LNP stability during freeze-drying [2].

6.4 Regulatory and Manufacturing Hurdles

Regulatory frameworks for veterinary mRNA vaccines are still evolving. Manufacturing scalability, quality control for dsRNA levels, and lot-to-lot consistency are areas requiring standardization. The absence of a prior precedent for nucleic acid vaccines in many veterinary jurisdictions presents a regulatory challenge.

7. Future Directions

7.1 Self-Amplifying mRNA (saRNA)

Self-amplifying mRNA incorporates replicase sequences from alphaviruses, enabling intracellular amplification of the antigen-encoding transcript. This reduces the required dose while prolonging antigen expression. saRNA platforms are particularly attractive for livestock where cost per dose is a critical factor.

7.2 Multivalent and Pan-Species Vaccines

Computational design of conserved epitopes across viral strains or related species (e.g., serotypes of Pasteurella multocida causing fowl cholera) can lead to pan-species vaccines. Machine learning algorithms can predict antigenic regions that elicit broad cross-reactivity, informed by genomic surveillance data.

7.3 Combination Vaccines

Co-formulation of multiple mRNA constructs targeting distinct pathogens can simplify vaccination schedules. For poultry, combination mRNA vaccines against Newcastle disease virus, infectious bronchitis virus, and avian influenza could be administered as a single injection.

7.4 Mucosal Delivery

Mucosal administration via intranasal or oral routes would induce secretory IgA responses at pathogen entry sites. Nanoparticle formulations containing mucoadhesive polymers or chitosan are being evaluated for respiratory and enteric pathogens in livestock and poultry.

8. Conclusion

mRNA vaccines have transitioned from experimental tools to clinical realities, driven by advances in sequence design, nucleoside modification, and lipid nanoparticle delivery. The platform offers unparalleled speed and flexibility for addressing emerging infectious diseases in veterinary medicine. Xu et al. (2025) provided a systematic framework for enhancing IVT mRNA effectiveness, while Pilkington et al. (2021) established the foundational principles of LNP delivery systems [1, 2]. Continued research into thermostable formulations, mucosal delivery, and species-specific immune profiling will be essential for translating these technologies into routine veterinary practice. The integration of mRNA vaccine platforms with existing diagnostic and surveillance networks promises to strengthen One Health approaches to infectious disease control.

References

[1] Xu L, Li C, Liao R, et al. From Sequence to System: Enhancing IVT mRNA Vaccine Effectiveness through Cutting-Edge Technologies. Mol Pharm. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/39601789/

[2] Pilkington EH, Suys EJA, Trevaskis NL, et al. From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases. Acta Biomater. 2021. URL: https://pubmed.ncbi.nlm.nih.gov/34153512/